BPC-157

Also known as: Body Protection Compound 157, PL 14736

**Mechanism of Action** BPC-157 (Body Protection Compound 157) is a stable gastric-derived pentadecapeptide (15 amino acids) that exerts pleiotropic effects on tissue repair. Its primary mechanism involves upregulation of vascular endothelial growth factor (VEGF) and modulation of the focal adhesion kinase (FAK)-paxillin pathway, enhancing cell migration and cytoskeletal dynamics. Additionally, it interacts with the nitric oxide (NO) system, promoting angiogenesis and blood flow to injured tissues. These actions collectively accelerate wound healing, reduce inflammation, and protect against oxidative stress in various organ systems. **Key Research Findings** Preclinical studies demonstrate BPC-157’s efficacy in accelerating healing of gastrointestinal ulcers, tendon-to-bone injuries, and skin wounds. It has shown protective effects against ischemia-reperfusion injury, colitis, and liver fibrosis in rodent models. Notably, BPC-157 enhances muscle and ligament recovery after trauma, reduces pain-related behaviors, and mitigates NSAID-induced enteropathy. Its ability to modulate the NO system also suggests potential benefits in vascular and neurological contexts, though human data remain absent. **Clinical Relevance** Despite extensive preclinical evidence, BPC-157 remains in the preclinical stage with no approved human clinical trials. Its therapeutic potential spans gastroenterology, orthopedics, and wound care, but safety, dosing, and efficacy in humans are unestablished. Regulatory status varies by region, and off-label use carries unknown risks. For research purposes only — not medical advice.

Key data

Research & studies

Frequently asked questions

Related peptides